Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clot Blood Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

NCT03173066
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Ferumoxytol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 10, 2026, 2:26 PM EDT
Terminated Phase 4 Interventional Results available

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

NCT03006562
View directory record Official record
Conditions
Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Subcutaneous Heparin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jun 10, 2026, 2:26 PM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Not applicable Interventional

The ATLANTIS Trial

NCT02553720
View directory record Official record
Conditions
Chronic Venous Hypertension Due to Deep Vein Thrombosis, Venous Reflux
Interventions
exercise in water, aquatic activity plus conventional management
Other
Lead sponsor
Arizona Cardiovascular Consultants
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

NCT04041843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jun 10, 2026, 2:26 PM EDT
Completed No phase listed Observational

Thrombosis Outcomes in Pediatric Venous Thromboembolism

NCT03068923
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jun 10, 2026, 2:26 PM EDT
Recruiting Not applicable Interventional

Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

NCT07002450
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Flutter
Interventions
Cardiac computed tomography angiography, Standard of care management
Diagnostic Test · Other
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT)

NCT03075761
View directory record Official record
Conditions
Post Thrombotic Syndrome, Deep Vein Thrombosis
Interventions
Fitbit, 30-minute education session
Device · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 21 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Fearon Algorithm in Warfarin Patient Self-Management

NCT03911661
View directory record Official record
Conditions
Atrial Fibrillation, Venous Thromboses, Heart Valve Diseases
Interventions
Fearon warfarin dosing algorithm, Usual care
Other
Lead sponsor
University of Utah
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jun 10, 2026, 2:26 PM EDT
Not listed No phase listed Observational

Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer

NCT02507180
View directory record Official record
Conditions
Pregnancy, Deep Vein Thrombosis
Interventions
LEFt clinical decision rule
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
16 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jun 10, 2026, 2:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06664502
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

Tadalafil for the Treatment of Raynaud's

NCT00822354
View directory record Official record
Conditions
Raynaud
Interventions
Tadalafil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Jun 10, 2026, 2:26 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jun 10, 2026, 2:26 PM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jun 10, 2026, 2:26 PM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jun 10, 2026, 2:26 PM EDT
Terminated Not applicable Interventional

Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection

NCT01608919
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
blood tests
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Dalteparin sodium injection, Warfarin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Jun 10, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

High-Shear Microfluidic Thrombosis Assay

NCT02422810
View directory record Official record
Conditions
Coagulation Defects, Other and Unspecified
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
45 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

The PEERLESS Study

NCT05111613
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
Catheter-Directed Thrombolysis, FlowTriever System
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Loma Linda, California • Orange, California • Pasadena, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

NCT04304508
View directory record Official record
Conditions
Acute Non-cardioembolic Ischemic Stroke
Interventions
BAY2433334, BAY2433334 matching placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
1,808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Golden Valley, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

NCT02829957
View directory record Official record
Conditions
Venous Thromboembolism, Menstruation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 10, 2026, 2:26 PM EDT
Completed No phase listed Observational

Outpatient Treatment of Low-risk Pulmonary Embolism

NCT02355548
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Outpatient Treatment of Pulmonary Embolism
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jun 10, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jun 10, 2026, 2:26 PM EDT